Quick detection of FKS1 mutations responsible for clinical echinocandin resistance in Candida albicans

Journal of Clinical Microbiology

Volumn 53, Issue 7, 2015, Pages 2037-2041

  Dudiuk, Catiana ^a,b   Gamarra, Soledad ^a   Jimenez Ortigosa, Cristina ^c   Leonardelli, Florencia ^a,b   Macedo, Daiana ^a   Perlin, David S ^c   Garcia Effron, Guillermo ^a,b  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINOCANDIN; ANTIFUNGAL AGENT; FUNGAL PROTEIN; MEMBRANE PROTEIN; MUTANT PROTEIN;

ACCURACY; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; FKS1 GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HOMOZYGOSITY; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; HUMAN; MICROBIAL SENSITIVITY TEST; MUTATION; PROCEDURES;

CANDIDA ALBICANS;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GENOTYPING TECHNIQUES; HUMANS; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTANT PROTEINS; MUTATION; SENSITIVITY AND SPECIFICITY;

EID: 84932597383     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00398-15     Document Type: Article

References (36)

1. Berdal JE, Haagensen R, Ranheim T, Bjornholt JV. 2014. Nosocomial candidemia; risk factors and prognosis revisited; 11 years experience from a Norwegian secondary hospital. PLoS One 9:e103916. http://dx.doi.org/10.1371/journal.pone.0103916.
2. Colombo AL, Guimaraes T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, Nouer SA, Nucci M. 2014. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: An analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 40:1489-1498. http://dx.doi.org/10.1007/s00134-014-3400-y.
3. Lopez Moral L, Tiraboschi IN, Schijman M, Bianchi M, Guelfand L, Cataldi S. 2012. Fungemia in hospitals of the city of Buenos Aires, Argentina. Rev Iberoam Micol 29:144-149. (In Spanish.) http://dx.doi.org/10.1016/j.riam.2011.11.001.
4. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, Guzman-Blanco M, Santolaya ME, Thompson L, Sifuentes-Osornio J, Echevarria JI, Colombo AL. 2013. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 8:e59373. http://dx.doi.org/10.1371/journal.pone.0059373.
5. Tang HJ, Liu WL, Lin HL, Lai CC. 2014. Epidemiology and prognostic factors of candidemia in cancer patients. PLoS One 9:e99103. http://dx.doi.org/10.1371/journal.pone.0099103.
6. Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS, Green M, Nania JJ, Bourque MR, Wise BA, Strohmaier KM, Taylor AF, Kartsonis NA, Chow JW, Arndt CA, DePauw BE, Walsh TJ. 2010. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 29:415-420. http://dx.doi.org/10.1097/INF.0b013e3181da2171.
7. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356:2472-2482. http://dx.doi.org/10.1056/NEJMoa066906.
8. Shorr AF, Wu C, Kothari S. 2011. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. J Antimicrob Chemother 66:375-380. http://dx.doi.org/10.1093/jac/dkq446.
9. Axner-Elings M, Botero-Kleiven S, Jensen RH, Arendrup MC. 2011. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden. J Clin Microbiol 49:2516-2521. http://dx.doi.org/10.1128/JCM.00201-11.
10. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O. 2012. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 18:86-90. http://dx.doi.org/10.3201/eid1801.110556.
11. Desnos-Ollivier M, Dromer F, Dannaoui E. 2008. Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol 46:2389-2392. http://dx.doi.org/10.1128/JCM.00053-08.
12. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: Implications for interpretive breakpoints. Antimicrob Agents Chemother 53:112-122. http://dx.doi.org/10.1128/AAC.01162-08.
13. Katiyar S, Pfaller M, Edlind T. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 50:2892-2894. http://dx.doi.org/10.1128/AAC.00349-06.
14. Liu W, Tan J, Sun J, Xu Z, Li M, Yang Q, Shao H, Zhang L, Liu W, Wan Z, Cui W, Zang B, Jiang D, Fang Q, Qin B, Qin T, Li W, Guo F, Liu D, Guan X, Yu K, Qiu H, Li R. 2014. Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study. J Antimicrob Chemother 69:162-167. http://dx.doi.org/10.1093/jac/dkt330.
15. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T. 2012. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 50:3435-3442. http://dx.doi.org/10.1128/JCM.01283-12.
16. Arendrup MC, Garcia-Effron G, Lass-Florl C, Lopez AG, Rodriguez-Tudela JL, Cuenca-Estrella M, Perlin DS. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 54:426-439. http://dx.doi.org/10.1128/AAC.01256-09.
17. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard-4th ed. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ES-CMIDEuropean Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for yeasts. Clin Microbiol Infect 14:398- 405. http://dx.doi.org/10.1111/j.1469-0691.2007.01935.x.
20. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49:3264-3273. http://dx.doi.org/10.1128/AAC.49.8.3264-3273.2005.
21. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10:121-130. http://dx.doi.org/10.1016/j.drup.2007.04.002.
22. Balashov SV, Park S, Perlin DS. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50:2058-2063. http://dx.doi.org/10.1128/AAC.01653-05.
23. Lachance MA, Boekhout T, Scorzetti G, Fell JW, Kurtzman CP. 2013. Candida Berkhout (1923). p 987-1278. In Kurtzman CP, Fell JW, Boekhout T (ed), The yeasts: a taxonomic study, 5th ed, vol 2. Elsevier, London, United Kingdom.
24. White TJ, Bruns TD, Lee SB, Taylor JW. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p 315-322. In Innis MA, Gelfand DH, Sninsky JJ, White TJ (ed), PCR protocols: A guide to methods and applications. Academic Press, San Diego, CA.
25. Sambrook J, Fritsch EF, Maniatis T. 1998. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
26. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43: 25-31. http://dx.doi.org/10.1086/504810.
27. Morrell M, Fraser VJ, Kollef MH. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640-3645. http://dx.doi.org/10.1128/AAC.49.9.3640-3645.2005.
28. Leon C, Ruiz-Santana S, Saavedra P, Castro C, Ubeda A, Loza A, Martin-Mazuelos E, Blanco A, Jerez V, Ballus J, Alvarez-Rocha L, Utande-Vazquez A, Farinas O. 2012. Value of beta-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med 38:1315-1325. http://dx.doi.org/10.1007/s00134-012-2616-y.
29. Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, Balasini C, Utande-Vazquez A, Gonzalez de Molina FJ, Blasco-Navalproto MA, Lopez MJ, Charles PE, Martin E, Hernandez-Viera MA. 2009. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study. Crit Care Med 37:1624-1633. http://dx.doi.org/10.1097/CCM.0b013e31819daa14.
30. Ostrosky-Zeichner L, Kullberg BJ, Bow EJ, Hadley S, Leon C, Nucci M, Patterson TF, Perfect JR. 2011. Early treatment of candidemia in adults: A review. Med Mycol 49:113-120. http://dx.doi.org/10.3109/13693786.2010.512300.
31. Arendrup MC, Perlin DS. 2014. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 27:484-492. http://dx.doi.org/10.1097/QCO.0000000000000111.
32. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. 10 November 2014. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med http://dx.doi.org/10.1101/cshperspect.a019752.
33. Perlin DS. 2014. Echinocandin resistance, susceptibility testing and prophylaxis: Implications for patient management. Drugs 74:1573-1585. http://dx.doi.org/10.1007/s40265-014-0286-5.
34. Jensen RH, Johansen HK, Arendrup MC. 2013. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother 57:614-617. http://dx.doi.org/10.1128/AAC.01193-12.
35. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. 2010. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 48:2373-2380. http://dx.doi.org/10.1128/JCM.02390-09.
36. Wiederhold NP, Grabinski JL, Garcia-Effron G, Perlin DS, Lee SA. 2008. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother 52:4145-4148. http://dx.doi.org/10.1128/AAC.00959-08.